title: Leishmaniasis: drugs in the clinic, resistance and new developments.
abstract: The control of Leishmania infections relies primarily on chemotherapy. The arsenal of drugs available for treating Leishmania infections is limited and includes pentavalent antimonials, pentamidine, amphotericin B, miltefosine, fluconazole and few other drugs at various stages of their development process. In this review, we will discuss the latest results regarding resistance mechanisms to drugs used in the clinic against Leishmania infections.
authors.affiliation: Centre de Recherche en Infectiologie du Centre de Recherche du CHUL and Division de Microbiologie, Faculté de Médecine, Université Laval, Que., Canada G1V 4G2. marc.ouellette@crchul.ulaval.ca
authors.forename: Marc
authors.initials: M
authors.lastname: Ouellette
authors.forename: Jolyne
authors.initials: J
authors.lastname: Drummelsmith
authors.forename: Barbara
authors.initials: B
authors.lastname: Papadopoulou
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004351:Drug Resistance / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends*
chemical_list: D000981:Antiprotozoal Agents